Economy

FDA Orders an Eye-Risk Warning on Every GLP-1 Drug: What Patients Should Know

By EcoPress Newsroom · November 14, 2026 · 8 min read

On November 9 the FDA required labels for Ozempic, Wegovy, Mounjaro, Zepbound and the rest of the class to warn of NAION, a rare cause of sudden vision loss. The agency calls it a potential risk, not a proven cause.

What changed

The US Food and Drug Administration announced on November 9 that makers of GLP-1 receptor agonists must add a warning about nonarteritic anterior ischemic optic neuropathy, or NAION, to their labels. The drugs named include semaglutide products (Ozempic, Rybelsus and Wegovy) and tirzepatide products (Mounjaro and Zepbound). Orforglipron is covered as well, and the requirement applies whichever condition the drug is prescribed for. The warning goes in the Warnings and Precautions section.

An Ozempic injection pen
An Ozempic injection pen. Illustrative image. Photo: HualinXMN, CC BY-SA 4.0, via Wikimedia Commons

What NAION is

NAION is damage to the optic nerve caused by reduced blood flow. It typically causes sudden, painless loss of vision in one eye and can be permanent. It is rare, and it occurs in people who have never taken these medicines.

What the evidence shows

The FDA cited a 2024 study and a review of trial data and concluded there is a potential increased risk. It also said NAION cases have been reported for every GLP-1 drug now on the market. European regulators went first: the European Medicines Agency concluded in June 2025 that NAION was a very rare side effect of semaglutide. Some secondary coverage notes that a pooled analysis of semaglutide and tirzepatide cannot reliably rank the two drugs against each other for safety.

What patients should do

Clinicians are being told to advise patients to report sudden, painless vision loss in one eye right away, to refer suspected cases to an ophthalmologist, and to consider stopping the drug unless the benefits clearly outweigh the risk. Patients should not stop a prescription on their own because of a headline. Anyone with questions, particularly people who already have eye disease or a history of optic nerve problems, should speak to the prescriber.

For the many people who take these drugs for diabetes or weight loss, the absolute risk remains very small. The change mainly means that the risk will now be spelled out in the same place as other serious warnings.

Also on EcoPress: Early Flu Season 2026: H1N1 Hospital Admissions Climb · Coffee, Flu Shots and Weight-Loss Surgery: How to Read This Week's Health Headlines

Sources and further reading: NeurologyLive; Healthline. Figures are as reported on the date of publication and may change.

Disclaimer: The information provided by EcoPress is for general informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other sort of advice. EcoPress does not recommend that any security, transaction, or investment strategy is suitable for any specific person. Readers should conduct their own research and consult with independent financial advisors before making any financial decisions. EcoPress is not responsible for any losses incurred as a result of using information published on this site.

About the Author

Leave a Comment

No comments yet.

Sponsored